Adenocyte
Ultrasound-enhanced Cytology for Earlier Pancreatic Cancer Detection
Company Overview
Snapshot
Founded in December 2020 by Mark Rutenberg, Adenocyte operates with 1–10 employees. In May 2026, the company secured an investment from iGan Partners, marking its first disclosed funding round.
Business overview
Adenocyte develops LINFU, a low-intensity non-focused ultrasound method designed to enhance cytology sample quality for cancer screening. This technology utilizes brief extracorporeal ultrasound exposure with microbubble contrast to increase the exfoliation of pancreatic ductal cells into pancreatic fluid, yielding richer cytology specimens for laboratory analysis. The company's initial application targets gastroenterologists, cytopathology labs, pancreatic cancer screening programs, and clinicians managing high-risk patients, aiming to detect pancreatic dysplasia and early ductal adenocarcinoma when interventions are most effective. Adenocyte operates within the Health Tech & Life Sciences sector, specifically focusing on Pharma & Medical Biotechnology and Medical Devices, with a specialization in Test Diagnostics & Screening and Diagnostics Devices.
Strategic signal
In May 2026, Adenocyte received an investment from iGan Partners. This funding validates the company's innovative approach to early pancreatic cancer detection and signals investor confidence in its LINFU technology, positioning Adenocyte for further development and potential market penetration in the health tech and life sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- What is Adenocyte's core technology?
- Adenocyte develops LINFU, a low-intensity non-focused ultrasound method that improves cytology sample quality in cancer screening by increasing the exfoliation of pancreatic ductal cells into pancreatic fluid for lab analysis.
- When was Adenocyte founded?
- Adenocyte was founded in December 2020.
- Who are the founders of Adenocyte?
- Adenocyte was founded by Mark Rutenberg.
- Which markets does Adenocyte primarily target?
- Adenocyte's first application targets gastroenterologists, cytopathology labs, pancreatic cancer screening programs, and clinicians managing high-risk patients, with the goal of detecting pancreatic dysplasia and early ductal adenocarcinoma.